Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with ...

(RTTNews) - Korro Bio, Inc., an RNA editing firm, and Frequency Therapeutics, Inc. (FREQ), announced on Friday that they have signed a deal to combine the two firms in an all-stock transaction. The ...

Venture-backed Korro Bio of Cambridge said Friday it will absorb financially struggling Frequency Therapeutics through a reverse merger in which Korro will take over Frequency’s public stock listing ...

Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program ...

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially ...

CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially ...